Juno Therapeutics (JUNO) Posts Q4 Loss of $1.61/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall St set for steady open as oil jumps ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts JUNO Hot Sheet
Join SI Premium – FREE
Juno Therapeutics (NASDAQ: JUNO) reported Q4 EPS of ($1.61), $1.28 worse than the analyst estimate of ($0.33).
For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can broadening earnings growth sustain the equity upcycle? JPM weighs in
- BofA keeps this stock as top pick as pricing power seen driving earnings upside
- UBS Reiterates Neutral Rating on Tractor Supply Company (TSCO) Amid Focus on Top-Line Trends
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
